Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 266.89B +53.9% |
| Revenue (ttm) | 57.04B +2.9% |
| Net Income | 7.75B -48.8% |
| EPS | 3.10 -48.0% |
| Shares Out | n/a |
| PE Ratio | 34.44 |
| Forward PE | 20.22 |
| Dividend | 2.89 (2.67%) |
| Ex-Dividend Date | Jun 15, 2026 |
| Volume | 656 |
| Open | 108.84 |
| Previous Close | 108.40 |
| Day's Range | 105.82 - 108.84 |
| 52-Week Range | 66.40 - 114.60 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Merck price target raised to $142 from $135 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Merck (MRK) to $142 from $135 and keeps an Outperform rating on the shares as part of a broader…
Merck price target raised to $140 from $135 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Merck (MRK) to $140 from $135 and keeps an Overweight rating on the shares. The firm updated the company’s pipeline…
Merck price target raised to $145 from $140 at Guggenheim
Guggenheim raised the firm’s price target on Merck (MRK) to $145 from $140 and keeps a Buy rating on the shares after updating the firm’s model ahead of the company’s…
Merck confirms FDA approves Keytruda combos with Padcev
Merck (MRK) announced the U.S. Food and Drug Administration approved KEYTRUDA and KEYTRUDA QLEX, Merck’s anti-PD-1 therapies, each in combination with Padcev, as neoadjuvant treatment and then continu...
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) a...
FDA approves Keytruda combos for certain muscle invasive bladder cancer cases
The Food and Drug Administration announced that it has approved pembrolizumab, or Keytruda, from Merck (MRK), or pembrolizumab and berahyaluronidase alfa-pmph, or Keytruda Qlex, also from Merck, each ...
Redwire appoints Paul Reichert, Niki Werkheiser as SpaceMD advisors
Redwire Corporation (RDW) has appointed Paul Reichert, former Principal Investigator at Merck Research Laboratories (MRK), and Niki Werkheiser, former Director of Technology Maturation at NASA’s Space...
Merck price target raised to $150 from $145 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Merck (MRK) to $150 from $145 and keeps an Overweight rating on the shares. The firm sees Merck’s Q2…
Merck price target raised to $150 from $135 at HSBC
HSBC analyst Rajesh Kumar raised the firm’s price target on Merck (MRK) to $150 from $135 and keeps a Buy rating on the shares. In a sector note on Healthcare,…
Merck terminates Phase 2 Alzheimer’s study
Merck (MRK) has terminated a Phase 2 randomized, placebo-controlled study that was intended to evaluate the efficacy and safety of MK-1167 as adjunctive therapy in participants with mild to moderate…
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4.
Merck price target raised to $155 from $136 at Scotiabank
Scotiabank raised the firm’s price target on Merck (MRK) to $155 from $136 and keeps an Outperform rating on the shares. The increase in price target is driven by multiple…
House committee opens probe into Merck, AbbVie China drug trials, Reuters says
A bipartisan group of U.S. lawmakers has opened national security investigations into whether drugmakers Merck (MRK) and AbbVie (ABBV) have been involved in clinical trials conducted in China that hel...
Merck price target raised to $141 from $130 at BofA
BofA raised the firm’s price target on Merck (MRK) to $141 from $130 and keeps a Buy rating on the shares, citing a sector re-rating for the firm’s raised target.
US House committee opens investigation into Merck, AbbVie China drug trials
The chair of the U.S. House Select Committee on China opened national security investigations into whether five drugmakers including Merck and AbbVie have been involved in clinical trials conducted i...
Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?
Merck extends its bullish breakout from a pennant pattern, supported by strong volume and higher swing lows, with technical structure pointing toward continued upside potential.
Merck price target raised to $155 from $136 at Scotiabank
Scotiabank raised the firm’s price target on Merck (MRK) to $155 from $136 and keeps an Outperform rating on the shares.
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Agreement to Improve Treatment Access for People Living with HIV. Agreement will help state ADAP programs provide access to IDVYNSO.
The Big 3: JPM, DHR, MRK
Dan Deming talks joins today's Big 3 and highlights JPMorgan Chase (JPM) as shares touch new record highs. He sees Danaher (DHR) as a candidate for a continuing breakout, noting a similar pattern in M...
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pe...
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with P...
Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets
NEW YORK--(BUSINESS WIRE)--Merck, through the company's Merck for Mothers initiative, and Mae are collaborating on a multi-state effort to expand and sustain the community-based doula workforce, with ...
Merck's bowel disease drug meets main goal in late-stage trial
Merck said on Monday its drug met the main goal in a late-stage trial testing it in patients with a type of inflammatory bowel disease.
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only ...
Merck's pneumococcal vaccine wins US approval for high-risk children, teens
Drugmaker Merck said on Thursday the U.S. health regulator has approved an expanded use of its pneumococcal vaccine for children and teenagers who face a higher risk of catching the bacterial diseas...